Your browser is no longer supported. Please, upgrade your browser.
ANAB [NASD]
AnaptysBio, Inc.
Index- P/E- EPS (ttm)-1.09 Insider Own0.20% Shs Outstand27.36M Perf Week-9.14%
Market Cap643.23M Forward P/E- EPS next Y-3.22 Insider Trans- Shs Float27.22M Perf Month-8.72%
Income-29.80M PEG- EPS next Q-0.11 Inst Own- Short Float11.49% Perf Quarter-3.81%
Sales71.20M P/S9.03 EPS this Y79.70% Inst Trans1.08% Short Ratio12.96 Perf Half Y-3.22%
Book/sh13.96 P/B1.68 EPS next Y-31.40% ROA-7.50% Target Price33.67 Perf Year25.67%
Cash/sh13.86 P/C1.69 EPS next 5Y- ROE-7.80% 52W Range13.92 - 35.85 Perf YTD9.07%
Dividend- P/FCF- EPS past 5Y-20.90% ROI-6.00% 52W High-34.53% Beta0.07
Dividend %- Quick Ratio26.70 Sales past 5Y33.70% Gross Margin- 52W Low68.64% ATR1.08
Employees94 Current Ratio26.70 Sales Q/Q-25.30% Oper. Margin-45.00% RSI (14)35.02 Volatility4.67% 4.19%
OptionableYes Debt/Eq0.00 EPS Q/Q-119.10% Profit Margin-41.90% Rel Volume0.13 Prev Close23.45
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume241.36K Price23.48
Recom2.60 SMA20-7.91% SMA50-5.93% SMA200-5.79% Volume12,165 Change0.11%
Jun-22-21Initiated H.C. Wainwright Buy $43
May-21-21Initiated UBS Neutral $29
Mar-16-21Upgrade Truist Hold → Buy
Mar-09-21Downgrade Wedbush Outperform → Neutral
Mar-08-21Downgrade JP Morgan Overweight → Underweight
Feb-11-21Upgrade JP Morgan Underweight → Overweight $40
Oct-27-20Upgrade Wedbush Neutral → Outperform $35
Oct-14-20Upgrade Guggenheim Neutral → Buy $36
Nov-08-19Downgrade Wedbush Outperform → Neutral
Nov-08-19Downgrade SunTrust Buy → Hold
Nov-08-19Downgrade JP Morgan Overweight → Underweight $109 → $17
Nov-08-19Downgrade Jefferies Buy → Hold $12
Jun-21-19Downgrade Stifel Buy → Hold $124 → $74
Jun-21-19Downgrade Credit Suisse Outperform → Neutral $137 → $79
Dec-20-18Initiated H.C. Wainwright Buy $126
Nov-21-18Initiated JP Morgan Overweight $115
Jul-19-18Initiated Credit Suisse Outperform $104
Apr-04-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-27-18Reiterated Stifel Buy $139 → $152
Mar-06-18Reiterated Stifel Buy $130 → $139
Jul-26-21 07:40PM  
May-27-21 04:15PM  
May-09-21 03:07AM  
May-04-21 05:35PM  
04:05PM  
Apr-28-21 12:33PM  
Apr-23-21 10:31AM  
Apr-22-21 04:12PM  
Apr-20-21 08:59AM  
Apr-12-21 04:00PM  
Mar-18-21 01:32AM  
Mar-16-21 03:06PM  
01:50PM  
Mar-12-21 06:07PM  
Mar-11-21 07:00PM  
Mar-09-21 09:38AM  
Mar-08-21 05:46PM  
08:28AM  
08:00AM  
Feb-26-21 06:55PM  
Feb-25-21 04:05PM  
Feb-23-21 06:41PM  
Feb-11-21 07:05PM  
Jan-07-21 04:15PM  
Nov-13-20 09:25AM  
Nov-04-20 04:00PM  
Oct-26-20 11:54PM  
08:00AM  
Oct-16-20 09:00AM  
Oct-14-20 04:19PM  
10:03AM  
Oct-13-20 09:00AM  
Oct-05-20 06:48AM  
Sep-28-20 06:43PM  
Sep-11-20 04:05PM  
Sep-01-20 07:36PM  
Aug-24-20 09:30AM  
Aug-21-20 09:24AM  
Aug-10-20 09:25AM  
08:05AM  
08:00AM  
Aug-06-20 12:30PM  
Aug-05-20 04:05PM  
Jul-31-20 08:30AM  
Jul-18-20 08:27PM  
Jul-15-20 08:30AM  
Jul-09-20 08:09AM  
Jul-07-20 12:29PM  
Jul-02-20 08:48PM  
Jun-22-20 12:00PM  
Jun-15-20 08:59AM  
Jun-10-20 11:30AM  
Jun-09-20 06:09PM  
May-27-20 07:33AM  
May-26-20 12:40PM  
12:10PM  
10:50AM  
10:49AM  
09:36AM  
May-25-20 10:50PM  
03:50PM  
02:30PM  
02:20PM  
01:00PM  
11:30AM  
10:35AM  
10:00AM  
09:08AM  
08:00AM  
07:40AM  
May-24-20 07:35PM  
01:48PM  
May-23-20 03:30PM  
02:30PM  
May-22-20 10:50PM  
05:45PM  
03:55PM  
03:15PM  
03:00PM  
02:15PM  
01:47PM  
01:21PM  
11:18AM  
10:43AM  
09:37AM  
May-21-20 08:00PM  
05:00PM  
03:00PM  
01:11PM  
01:00PM  
01:00PM  
12:00PM  
10:32AM  
09:28AM  
06:20AM  
May-20-20 10:50PM  
02:30PM  
02:00PM  
01:46PM  
12:16PM  
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Suria HamzaPresident, CEOMay 12Option Exercise1.1210,00011,20057,636May 13 04:50 PM
EcoR1 Capital, LLCDirectorMay 04Buy23.25165,0003,835,7557,520,424May 04 04:51 PM
EcoR1 Capital, LLCDirectorMay 03Buy23.3120,800484,8737,355,424May 04 04:51 PM
EcoR1 Capital, LLCDirectorApr 30Buy23.1635,700826,8167,334,624May 04 04:51 PM
EcoR1 Capital, LLCDirectorApr 27Buy23.8233,800805,0897,298,924Apr 27 06:23 PM
EcoR1 Capital, LLCDirectorApr 26Buy23.8013,900330,8597,265,124Apr 27 06:23 PM
EcoR1 Capital, LLCDirectorApr 23Buy23.5499,6002,344,2857,251,224Apr 27 06:23 PM
EcoR1 Capital, LLC10% OwnerMar 09Buy18.70531,0009,928,4267,151,624Mar 10 05:53 PM
EcoR1 Capital, LLC10% OwnerMar 08Buy18.972,777,80052,694,3106,620,624Mar 10 05:53 PM
EcoR1 Capital, LLC10% OwnerFeb 23Buy25.4829,500751,6573,842,824Feb 25 05:58 PM
LOUMEAU ERIC JCOO, General CounselFeb 12Option Exercise14.0210,000140,20010,000Feb 12 09:28 PM
LOUMEAU ERIC JCOO, General CounselFeb 12Sale35.0010,000350,0000Feb 12 09:28 PM